CEP170B

Across TCGA pan-cancer cohorts, CEP170B RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CEP170B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CEP170B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CEP170B is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

HNSC, LIHC, and KIRC are the cancer types where CEP170B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEP170B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.950	<.001	10	view →
LIHC	Female	II,III,IV	+1.280	<.001	9	view →
KIRC	Male	II,III,IV	−0.787	<.001	9	view →
THCA	Male	All	+0.768	<.001	9	view →
LUSC	Male	II,III,IV	+0.951	<.001	7	view →
STAD	All	II,III,IV	+0.882	.002	6	view →
CHOL	Male	All	+2.466	<.001	5	view →
COAD	Female	All	−0.378	.010	4	view →
ESCA	All	All	+0.839	.036	1	view →
COAD	Female	IV	+0.399	<.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 9 lineages.

CEP170B–HNSC

Open the HNSC breakdown →